InsidersTradesSigma
Follow the ALX Oncology Holdings INC stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, ALX Oncology Holdings INC has logged 102 public disclosures. Market capitalisation: €276.6m. The latest transaction was reported on 18 August 2026 (Cession). Among the most active insiders: Pons Jaume. Every trade is free.
102
Insider Decl.
n/a
Thresholds
€5m
7 ops.
Buy Volume
€7m
57 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate ALX Oncology Holdings INC Strong Buy (bullish), based on 5 analysts. Average price target: US$4.60.
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 August 2026
Declarations102 total
573 shares@ US$1.930.0004% mcap27.5% of flowCommon StockSEC:0001193125-26-355761:0
2,230 shares@ US$1.930.0016% mcap0.3% of flowCommon StockSEC:0001193125-26-355764:0
1,404 shares@ US$2.040.0010% mcap100.0% of flowCommon StockSEC:0001193125-26-296246:0
12,311 shares@ US$2.171.7% of flowCommon StockSEC:0001193125-26-119705:0
903 shares@ US$2.171.3% of flowCommon StockSEC:0001193125-26-119703:0
565 shares@ US$2.270.8% of flowCommon StockSEC:0001193125-26-061313:0
2,201 shares@ US$2.270.3% of flowCommon StockSEC:0001193125-26-060037:0
3,184,713 shares@ US$1.57100.0% of flowCommon StockSEC:0001278411-26-000002:0
Canonical exit: 3 May 2026 (T+90)
3,925 shares@ US$1.112.6% of flowCommon StockSEC:0001193125-26-006374:0
21,070 shares@ US$1.0661.3% of flowCommon StockSEC:0001193125-25-207432:0
Canonical exit: 15 Dec 2025 (T+90)
75,000 shares@ US$0.7787100.0% of flowCommon StockSEC:0000950170-25-110434:0
Canonical exit: 16 Nov 2025 (T+90)
2,382 shares@ US$0.64040.0% of flowCommon StockSEC:0000950170-25-110099:0
611 shares@ US$0.64040.2% of flowCommon StockSEC:0000950170-25-110102:0
2,011 shares@ US$0.45010.6% of flowCommon StockSEC:0000950170-25-094613:0
1,532 shares@ US$0.430.4% of flowCommon StockSEC:0000950170-25-092232:0
42,000 shares0Common StockSEC:0001415889-25-008417:0
3,000 shares0Common StockSEC:0001415889-25-008428:0
2,159 shares@ US$1.15020.1% of flowCommon StockSEC:0001415889-25-005067:0
1,326 shares@ US$1.15020.0% of flowCommon StockSEC:0001415889-25-005069:0
550 shares@ US$1.15020.5% of flowCommon StockSEC:0001415889-25-005071:0
2,221 shares@ US$1.802.9% of flowCommon StockSEC:0001415889-25-001120:0
1,426 shares@ US$1.58021.6% of flowCommon StockSEC:0001415889-25-000132:0
10,796 shares@ US$1.58020.3% of flowCommon StockSEC:0001415889-25-000123:0
30,000 shares@ US$1.5468100.0% of flowCommon StockSEC:0001415889-24-028247:0
Canonical exit: 2 Mar 2025 (T+90)
2,191 shares@ US$2.580.2% of flowCommon StockSEC:0001415889-24-021471:0
25 of 102 declarations
关于 ALX Oncology Holdings INC
ALX Oncology Holdings Inc.（股票代码：ALXO）是一家在美国纳斯达克上市的生物技术公司，作为一家临床阶段的肿瘤开发商而非商业阶段的药物制造商运营。公司总部位于加利福亚州南旧金山，专注于免疫肿瘤项目，旨在帮助免疫系统识别并攻击癌症。根据公司通讯，ALX Oncology 于2020年4月1日注册成立为特拉华州公司，而其运营历史可追溯至2015年成立之时。([alxoncology.com](https://alxoncology.com/about-us/?utm_source=openai)) 公司的主要资产是 evorpacept，一种新型的 CD47 靶向研究性疗法。实际上，ALX 正在推行“不要吃我”信号阻断策略：通过抑制 CD47，evorpacept 旨在帮助先天免疫系统识别肿瘤细胞，并可能增强其他抗癌药物的活性。其产品线围绕联合治疗方案构建，特别是与抗癌抗体、抗体-药物偶联物（ADCs）以及选定的检查点抑制剂方法结合。最近，管理层强调了在 HER2 阳性肿瘤、胃癌和胃食管结合部癌、乳腺癌以及某些血液系统恶性肿瘤方面的临床活性。公司还在推进 ALX2004，一种 EGFR 靶向 ADC，该药物于2025年获得美国 FDA IND 批准并进入1期开发。([alxoncology.com](https://alxoncology.com/our-approach/evorpacept/?utm_source=openai)) 从竞争角度来看，ALX Oncology 在一个高度拥挤且科学要求严苛的癌症药物开发领域运营。其投资案例取决于 evorpacept 是否能展示出与其他免疫肿瘤和靶向治疗组合相比差异化的疗效和安全性，同时将早期临床信号转化为注册机会。2025年和2026年的最新更新强调了在 HER2 阳性胃癌、惰性 B 细胞非霍奇金淋巴瘤和 HER2 阳性乳腺癌方面的积极数据，而之前在头颈癌方面的一些研究未能达到其主要终点。这种有希望的信号和临床挫折的混合是开发阶段生物技术公司的典型特征，应被视为风险/回报框架的一部分。([ir.alxoncology.com](https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-presents-positive-updated-data-aspen-06-phase-2/?utm_source=openai)) 从地理上看，公司以南旧金山为中心，拥有美国运营基地，而其临床足迹通过研究者发起的试验、学术合作和多中心试验得以扩展。公司近期里程碑包括在主要肿瘤学会议上披露更多临床数据、ALX2004 的持续进展以及2026年的股权发行，后者增强了资产负债表并为正在进行的开发提供了资金。因此，对于法国、比利时和瑞士的投资者而言，ALXO 应被视为一家投机性的纳斯达克上市肿瘤公司，其估值将主要由临床结果、产品线执行和未来融资需求驱动，而非当前产品销售。([ir.alxoncology.com](https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-reports-first-quarter-2026-financial-results-and?utm_source=openai))
